[Leukodepletion of blood products: a requirement for improvement of quality and safety].
The presence of leukocytes in blood products has no beneficial effect on the recipient, except in special situations such as for patients being prepared to receive an organ transplantation. On the other hand the leukocytes have a number of untoward side effects such as HLA immunisation, non haemolytic febrile transfusion reactions, virus transmission and postoperative infections. In response to a request of the Minister of Health, Welfare and Sports, the Health Council of the Netherlands prepared a recommendation on the need of routine leukodepletion by filtration of blood. Although the introduction of leukodepletion of blood products is favoured, it is emphasized that only data from selected patient groups are available while the costs of leukodepletion are considerable. Therefore, an evaluation of the benefits and cost effectiveness of blood filtration is recommended. It is argued that leukodepletion, already introduced in a number of countries, is now considered to be 'state of the art'. Furthermore product liability, public opinion about blood safety and the precaution duty of manufacturers should be taken into account.
van Aken
W G
WG
Sanquin/Centraal Laboratorium van de Bloedtransfusiedienst, Amsterdam.
Brand
A
A
van der Poel
C L
CL
D001771:Blood Banks / Q000191:economics / Q000592:standards / Q000639:trends*; D001781:Blood Component Removal / Q000191:economics / Q000379:methods; D001803:Blood Transfusion / Q000592:standards*; D003257:Consumer Product Safety / Q000592:standards*; D003362:Cost-Benefit Analysis; D006801:Humans; D007962:Leukocytes / Q000276:immunology* / Q000821:virology; D016365:Liability, Legal; D009426:Netherlands; D065227:Transfusion Reaction; D006113:United Kingdom
Leukodepletie van bloedproducten: een maatregel ten behoeve van kwaliteit en veiligheid.